Evidence map›Paper›PMID 23445273›Full record

ArticleTransfusion2013

Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk.

Marion Vermeulen, Charl Coleman, Josephine Mitchel, Ravi Reddy, Harry van Drimmelen, Tracy Fickett, Michael Busch, Nico Lelie

Open access · greenAbstract readComparative Study
In one paragraph

Article in Transfusion, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. The Performance of the Current Algorithm of HIV Diagnosis.Iranian journal of public health · 2024
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Human Immunodeficiency Virus (HIV).Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2016
    Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Marion VermeulenSouth African National Blood Service (SANBS), Johannesburg, South Africa; BioQControl, DDL Laboratories, Rijswijk, Netherlands; Creative Testing Solutions, Tampa, Florida; Blood Systems Research Institute, San Francisco, California; Lelie Research Paris, Paris, France.
Charl Coleman
Josephine Mitchel
Ravi Reddy
Harry van Drimmelen
Tracy Fickett
Michael Busch
Nico Lelie
DDL Diagnostic Laboratory · NLSouth African National Blood Service · ZABlood Systems Research Institute · US

Funding

Health Outcomes in Blood Donors and RecipientsK24HL075036 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MURPHY, EDWARD L · 2004 to 2013
$1.6M
NHLBI NIH HHS K24 HL075036
6 · The paper itself

Abstract

backgroundAfter 3 years of individual-donation nucleic acid test (ID-NAT) screening by the South African National Blood Service (SANBS), a repository of 73 human immunodeficiency virus antibody (anti-HIV)-negative window period (WP)-yield samples and 28 anti-HIV-positive, HIV-RNA-negative elite controllers (ECs) became available for comparison of a p24 antigen (p24 Ag) assay (Innogenetics), two viral load assays (Siemens branch DNA [bDNA] 3.0 and Abbott real-time polymerase chain reaction [RT-PCR]), and three triplex NAT assays (Novartis Diagnostics Ultrio and Ultrio-Plus and Roche TaqScreen) by replicate testing of dilutions. STUDY DESIGN AND

methodsViral loads were assessed by bDNA and RT-PCR assays and if below 100 copies (cps)/mL, by Ultrio limiting dilution probit analysis. The probability of virus transmission by WP and EC donations was estimated for different levels of the 50% minimum infectious dose (ID50 ) using Poisson distribution statistics.

resultsThe equal distribution of WP donations plotted by log HIV-RNA levels indicated a random appearance of donors in the ramp-up phase. The HIV p24 Ag assay detected 45% of WP samples and the cutoff crossing point was estimated at 8140 (bDNA)/22,710 (RT-PCR) cps/mL. On replicate retesting of 40 HIV p24 Ag-negative ID-NAT WP-yield samples Ultrio minipool (MP)8, Ultrio-Plus MP8, and TaqScreen MP6 detected 79, 81, and 78%, respectively. Modeling with an estimated ID50 of 31.6 virions/RBC indicated that 15% of p24 Ag-negative ID-NAT WP-yield donations would have transmitted HIV if MP6-8 NAT had been used. Only 2% of RBC transfusions from ECs are estimated to be infectious with a worst-case ID50 estimate of 316 virions.

conclusionOur analysis of viremia and infectivity of WP and EC donations enables comparison of the efficacy of NAT options in preventing HIV transmission risk.

Indexed as

AlgorithmsAsymptomatic DiseasesBlood DonorsCase-Control StudiesHIV-1HIV Core Protein p24HIV InfectionsHumansReal-Time Polymerase Chain ReactionRisk FactorsRNA, ViralSerologic TestsSouth AfricaViral LoadHIV Core Protein p24RNA, Viral

Identifiers

PMID23445273
PMCPMC5061040
OpenAlexW1905270355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.